V900102
Sodium succinate dibasic hexahydrate
98%, Vetec™, reagent grade
Synonym(s):
Butanedioic acid disodium salt, Succinic acid disodium salt
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
NaOOCCH2CH2COONa · 6H2O
CAS Number:
Molecular Weight:
270.14
UNSPSC Code:
12352100
PubChem Substance ID:
EC Number:
205-778-7
Beilstein/REAXYS Number:
3921044
MDL number:
Assay:
98%
Grade:
reagent grade
Product Name
Sodium succinate dibasic hexahydrate, Vetec™, reagent grade, 98%
InChI
1S/C4H6O4.2Na.6H2O/c5-3(6)1-2-4(7)8;;;;;;;;/h1-2H2,(H,5,6)(H,7,8);;;6*1H2/q;2*+1;;;;;;/p-2
InChI key
ZBTUYCUNQBRXOR-UHFFFAOYSA-L
SMILES string
O.O.O.O.O.O.[Na+].[Na+].[O-]C(=O)CCC([O-])=O
grade
reagent grade
product line
Vetec™
assay
98%
Looking for similar products? Visit Product Comparison Guide
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jun Kimura et al.
Cancer science, 104(8), 1083-1090 (2013-05-18)
Pancreatic cancer has a poor prognosis after complete macroscopic resection combined with chemotherapy. Even after neoadjuvant chemotherapy, R0 resection is often not possible. Moreover, current imaging techniques cannot reliably distinguish viable cancer cells from scar tissue at the resectional margin.
Ilya B Zavodnik et al.
Life sciences, 92(23), 1110-1117 (2013-05-07)
The present study was designed for further evaluation of the biochemical mechanism of hepatic mitochondrial dysfunction under oxidative damages induced by organic hydroperoxide, tert-butyl hydroperoxide (tBHP), for estimation of the molecular targets impaired during oxidative stress, and for investigation of
Hiroshi Yoneyama et al.
Anti-cancer drugs, 26(1), 90-100 (2014-09-05)
The efficacy of gemcitabine (GEM), a standard treatment agent for pancreatic cancer, is insufficient because of primary or acquired resistance to this drug. Patients with tumors intrinsically sensitive to GEM gradually acquire resistance and require a shift to second agents
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service